Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $789,097 - $981,979
5,955 New
5,955 $802,000
Q4 2021

Jan 28, 2022

SELL
$107.43 - $135.93 $261,592 - $330,989
-2,435 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $259,084 - $294,099
2,435 New
2,435 $263,000
Q4 2020

Feb 08, 2021

SELL
$80.49 - $108.67 $1.69 Million - $2.28 Million
-20,944 Closed
0 $0
Q3 2020

Nov 13, 2020

SELL
$85.91 - $100.83 $1.03 Million - $1.21 Million
-11,996 Reduced 36.42%
20,944 $1.83 Million
Q2 2020

Aug 13, 2020

BUY
$73.37 - $98.18 $2.42 Million - $3.23 Million
32,940 New
32,940 $3.23 Million
Q1 2020

Apr 21, 2020

SELL
$64.5 - $97.79 $6.27 Million - $9.51 Million
-97,211 Closed
0 $0
Q4 2019

Feb 06, 2020

BUY
$72.13 - $90.25 $7.01 Million - $8.77 Million
97,211 New
97,211 $8.61 Million
Q3 2019

Nov 08, 2019

SELL
$62.98 - $75.72 $21.1 Million - $25.3 Million
-334,347 Closed
0 $0
Q2 2019

Jul 31, 2019

BUY
$65.7 - $83.98 $807,387 - $1.03 Million
12,289 Added 3.82%
334,347 $24.3 Million
Q1 2019

May 03, 2019

BUY
$77.14 - $90.79 $24.8 Million - $29.2 Million
322,058 New
322,058 $26 Million
Q4 2018

Feb 06, 2019

SELL
$77.85 - $96.01 $28.9 Million - $35.6 Million
-370,702 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$88.91 - $98.84 $2.34 Million - $2.61 Million
26,369 Added 7.66%
370,702 $35.1 Million
Q2 2018

Aug 09, 2018

BUY
$89.78 - $106.23 $17.4 Million - $20.6 Million
193,863 Added 128.84%
344,333 $31.9 Million
Q1 2018

May 08, 2018

BUY
$92.01 - $123.21 $13.8 Million - $18.5 Million
150,470 New
150,470 $14.2 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $353B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Stevens Capital Management LP Portfolio

Follow Stevens Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stevens Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Stevens Capital Management LP with notifications on news.